Xeris Biopharma Holdings Inc <XERS.OQ> expected to post a loss of 6 cents a share - Earnings Preview
Xeris Biopharma Holdings Inc XERS.OQ XERS.O is expected to show a rise in quarterly revenue when it reports results on March 6 for the period ending December 31 2024
The Chicago Illinois-based company is expected to report a 30.9% increase in revenue to $58.104 million from $44.39 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Xeris Biopharma Holdings Inc is for a loss of 6 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc is $5.00, above its last closing price of $3.69.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.10 | -0.09 | -0.11 | Missed | -22.2 |
Jun. 30 2024 | -0.11 | -0.11 | -0.10 | Beat | 6.3 |
Mar. 31 2024 | -0.12 | -0.12 | -0.14 | Missed | -20 |
Dec. 31 2023 | -0.10 | -0.10 | -0.10 | Met | -2 |
Sep. 30 2023 | -0.12 | -0.12 | -0.09 | Beat | 22.4 |
Jun. 30 2023 | -0.13 | -0.13 | -0.14 | Missed | -9.8 |
Mar. 31 2023 | -0.17 | -0.17 | -0.12 | Beat | 28.4 |
Dec. 31 2022 | -0.16 | -0.16 | -0.10 | Beat | 36.5 |
This summary was machine generated March 4 at 14:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
All Eyes on August CPI: The Data That Could Trigger a Jumbo Fed Cut — Or Not
TradingKey - The key question now is whether the August CPI report, to be released on September 11, could push the Fed toward a more aggressive 50-basis-point cut — as it did in September 2024.
Oracle Q1 FY2026 Earnings: Cloud Surge and Record RPO Fuel AI Optimism
TradingKey - Oracle Corporation (NYSE: ORCL) posted mixed Q1 FY2026 results, with total revenue and adjusted EPS slightly below consensus amid a shift to cloud services, but cloud revenue beat expectations with robust 28% growth. A massive RPO backlog of $455 billion, up 359% YoY
U.S. August CPI Preview: Persistent Rise in Inflation, What Impact on Rate Cuts? And on US Stocks?
TradingKey - On 11 September 2025, the U.S. will publish August CPI data. Consensus forecasts indicate a 0.3% month-over-month increase for both headline CPI and core CPI. As a result, headline CPI year-over-year may climb to 2.9%, up from 2.7%
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks ahead
2025 Hottest US IPO Week: Klarna, Gemini, Figure Set for “Triple Launch”
TradingKey - 5 companies are now pricing their U.S. initial public offerings (IPOs) for the week starting September 8, with a total expected fundraising exceeding $3 billion, making it the busiest IPO week of 2025. Investors are closely watching the debut performance of Klarna, Gemini, and Figure.
